Literature DB >> 21951763

Differentiating diabetic foot ulcers that are unlikely to heal by 12 weeks following achieving 50% percent area reduction at 4 weeks.

Robert A Warriner1, Robert J Snyder, Matthew H Cardinal.   

Abstract

This retrospective analysis included intent-to-treat control patient data from two published, randomised, diabetic foot ulcer (DFU) trials in an effort to differentiate ulcers that are unlikely to heal by 12 weeks despite early healing progress [≥50% percent area reduction (PAR) at 4 weeks]. Predicted and actual wound area trajectories in DFUs that achieved early healing progress were analysed from weeks 5 to 12 and compared for ulcers that did and did not heal at 12 weeks. In 120 patients who achieved ≥50% PAR by week 4, 62 (52%) failed to heal by 12 weeks. Deviations from the predicted healing course were evident by 6 weeks for non healing ulcers. A 2-week delay in healing significantly lowered healing rates (P = 0·001). For DFUs with ≥50% PAR at 4 weeks, those achieving ≥90% versus <90% PAR at 8 weeks had a 2·7-fold higher healing rate at 12 weeks (P = 0·001). A PAR of <90% at 8 weeks provided a negative predictive value for DFU healing at 12 weeks of 82%. For ulcers that fail to progress or worsen from weeks 4 to 6, and those that fail to achieve 90% PAR at 8 weeks, reevaluation of the wound and its treatment is recommended.
© 2011 The Authors. © 2011 Blackwell Publishing Ltd and Medicalhelplines.com Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21951763      PMCID: PMC7950518          DOI: 10.1111/j.1742-481X.2011.00860.x

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  15 in total

1.  Quality of life of adults with unhealed and healed diabetic foot ulcers.

Authors:  Donna Goodridge; Elly Trepman; Jeff Sloan; Lorna Guse; Laurel A Strain; John McIntyre; John M Embil
Journal:  Foot Ankle Int       Date:  2006-04       Impact factor: 2.827

2.  Surrogate end points for the treatment of diabetic neuropathic foot ulcers.

Authors:  David J Margolis; Joel M Gelfand; Ole Hoffstad; Jesse A Berlin
Journal:  Diabetes Care       Date:  2003-06       Impact factor: 19.112

Review 3.  Clinical practice. Neuropathic diabetic foot ulcers.

Authors:  Andrew J M Boulton; Robert S Kirsner; Loretta Vileikyte
Journal:  N Engl J Med       Date:  2004-07-01       Impact factor: 91.245

4.  Risk factors for foot infections in individuals with diabetes.

Authors:  Lawrence A Lavery; David G Armstrong; Robert P Wunderlich; M Jane Mohler; Christopher S Wendel; Benjamin A Lipsky
Journal:  Diabetes Care       Date:  2006-06       Impact factor: 19.112

5.  Incidence, outcomes, and cost of foot ulcers in patients with diabetes.

Authors:  S D Ramsey; K Newton; D Blough; D K McCulloch; N Sandhu; G E Reiber; E H Wagner
Journal:  Diabetes Care       Date:  1999-03       Impact factor: 19.112

Review 6.  What is the most effective way to reduce incidence of amputation in the diabetic foot?

Authors:  J Apelqvist; J Larsson
Journal:  Diabetes Metab Res Rev       Date:  2000 Sep-Oct       Impact factor: 4.876

7.  Evaluation of the use of prognostic information for the care of individuals with venous leg ulcers or diabetic neuropathic foot ulcers.

Authors:  Shanu K Kurd; Ole J Hoffstad; Warren B Bilker; David J Margolis
Journal:  Wound Repair Regen       Date:  2009 May-Jun       Impact factor: 3.617

8.  Pathways to diabetic limb amputation. Basis for prevention.

Authors:  R E Pecoraro; G E Reiber; E M Burgess
Journal:  Diabetes Care       Date:  1990-05       Impact factor: 19.112

9.  The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial.

Authors:  William A Marston; Jason Hanft; Paul Norwood; Richard Pollak
Journal:  Diabetes Care       Date:  2003-06       Impact factor: 19.112

10.  Molecular markers in patients with chronic wounds to guide surgical debridement.

Authors:  Harold Brem; Olivera Stojadinovic; Robert F Diegelmann; Hyacinth Entero; Brian Lee; Irena Pastar; Michael Golinko; Harvey Rosenberg; Marjana Tomic-Canic
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

View more
  9 in total

1.  Outcomes and prognosis of diabetic foot ulcers treated by an interdisciplinary team in Canada.

Authors:  Jérôme Patry; André Tourigny; Marie-Philippe Mercier; Clermont E Dionne
Journal:  Int Wound J       Date:  2020-11-25       Impact factor: 3.315

2.  A prospective, randomised comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers.

Authors:  Charles M Zelen; Thomas E Serena; Robert J Snyder
Journal:  Int Wound J       Date:  2014-02-21       Impact factor: 3.315

3.  A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers.

Authors:  Charles M Zelen; Thomas E Serena; Guilhem Denoziere; Donald E Fetterolf
Journal:  Int Wound J       Date:  2013-06-07       Impact factor: 3.315

Review 4.  Components and Quality Measures of DIME (Devitalized Tissue, Infection/Inflammation, Moisture Balance, and Edge Preparation) in Wound Care.

Authors:  Robert J Snyder; Caroline Fife; Zena Moore
Journal:  Adv Skin Wound Care       Date:  2016-05       Impact factor: 2.347

5.  Wound Closure in Smoking Peripheral Arterial Disease Patients With Treatment-Refractory Ulcerations: A 12-Month Follow-up Case Series.

Authors:  Jonathan Smedley; Georgina M Michael; Yeabsera G Tamire
Journal:  Int J Low Extrem Wounds       Date:  2016-11-16       Impact factor: 2.057

6.  Human amniotic membrane dressing for the treatment of an infected wound due to an entero-cutaneous fistula: Case report.

Authors:  Dimitri Barski; Holger Gerullis; Thorsten Ecke; Gabriella Varga; Mihaly Boros; Isabel Pintelon; Jean-Pierre Timmermans; Thomas Otto
Journal:  Int J Surg Case Rep       Date:  2018-08-13

7.  Potential prognostic factors for delayed healing of common, non-traumatic skin ulcers: A scoping review.

Authors:  David A Jenkins; Sundus Mohamed; Joanne K Taylor; Niels Peek; Sabine N van der Veer
Journal:  Int Wound J       Date:  2019-02-28       Impact factor: 3.315

8.  The Queensland high risk foot form (QHRFF) - is it a reliable and valid clinical research tool for foot disease?

Authors:  Peter A Lazzarini; Vanessa Ng; Ewan M Kinnear; Maarten C Kamp; Suzanne S Kuys; Cameron Hurst; Lloyd F Reed
Journal:  J Foot Ankle Res       Date:  2014-01-28       Impact factor: 2.303

9.  An observational pilot study using a purified reconstituted bilayer matrix to treat non-healing diabetic foot ulcers.

Authors:  David G Armstrong; Dennis P Orgill; Robert D Galiano; Paul M Glat; Jarrod P Kaufman; Marissa J Carter; Charles M Zelen
Journal:  Int Wound J       Date:  2020-04-07       Impact factor: 3.315

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.